Orforglipron Capsules 6mg
Orforglipron (LY3502970) is a once-daily, oral, non-peptide small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly.
$199.99
In stock
Research goals: Metabolic & Weight
Description
Orforglipron (LY3502970) is a once-daily, oral, non-peptide small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. Unlike injectable peptide GLP-1 agonists and oral semaglutide, orforglipron is administered without food, beverage, or water restrictions, and across the published Phase 2 and Phase 3 ACHIEVE and ATTAIN program it has produced clinically significant reductions in HbA1c and body weight in adults with type 2 diabetes, obesity, or overweight with weight-related comorbidity.
The strongest evidence base comes from the ATTAIN-1 Phase 3 trial in 3,127 adults with obesity without diabetes: at 72 weeks, orforglipron 36 mg produced a mean weight reduction of 12.4% versus 2.1% for placebo, with 59.6% of high-amount participants losing at least 10% of body weight (Wharton et al., NEJM 2025).3
Published Research on Orforglipron
Phase 2 Obesity Amount-finding — Wharton et al., New England Journal of Medicine (2023)
The pivotal Phase 2 trial in 272 adults with obesity or overweight plus a weight-related coexisting condition (without diabetes) randomized participants to placebo or one of four orforglipron amounts (12, 24, 36, or 45 mg) for 36 weeks. At week 26, mean placebo-subtracted weight loss reached approximately 10.6% at the highest amount; by week 36, mean reductions of up to 14.7% were observed. The most common adverse events were concentration-dependent gastrointestinal symptoms (nausea, diarrhea, vomiting, constipation), generally mild to moderate and concentrated during escalating-amount.1
Phase 2 Type 2 Diabetes Head-to-Head — Frias et al., The Lancet (2023)
This 26-week, multicenter, double-blind, randomized Phase 2 study enrolled adults with type 2 diabetes inadequately controlled on diet and exercise alone, comparing five amounts of orforglipron with placebo and the injectable GLP-1 agonist dulaglutide 1.5 mg. The authors concluded that orforglipron at amounts of 12 mg or greater showed significant reductions in HbA1c and bodyweight compared with placebo or dulaglutide
, with HbA1c reductions of up to −2.1% versus −1.1% for dulaglutide and −0.43% for placebo.2
ATTAIN-1 Phase 3 Obesity Trial — Wharton et al., New England Journal of Medicine (2025)
The pivotal registrational Phase 3 trial enrolled 3,127 adults with obesity (or overweight with a weight-related condition) and without diabetes, randomized 3:3:3:4 to orforglipron 6 mg, 12 mg, 36 mg, or placebo for 72 weeks. At 72 weeks, mean body weight reductions were 7.5%, 8.4%, and 11.2% for the three orforglipron amounts versus 2.1% for placebo, with parallel improvements in waist circumference, blood pressure, triglycerides, and non-HDL cholesterol. Gastrointestinal adverse events drove a study discontinuation rate of up to 10% at the highest amount.3
ACHIEVE-1 Phase 3 Type 2 Diabetes Trial — Rosenstock et al., New England Journal of Medicine (2025)
The first Phase 3 trial in adults with early type 2 diabetes inadequately controlled on diet and exercise randomized participants 1:1:1:1 to orforglipron 3 mg, 12 mg, or 36 mg or placebo once daily for 40 weeks. All three amounts met the primary endpoint of superior HbA1c reduction versus placebo (mean reductions of 1.3% to 1.6% from a baseline of 8.0%), and more than 65% of participants on the highest amount achieved an HbA1c at or below 6.5%. Mean body weight reduction at 40 weeks reached 7.9% at the highest amount, with weight not yet plateaued at trial end.4
About the Compound
Orforglipron is a small-molecule, non-peptide, partial agonist of the GLP-1 receptor, structurally distinct from native GLP-1 and from peptide-based GLP-1 agonists such as semaglutide, liraglutide, and dulaglutide. Its non-peptide chemistry enables once-daily oral administration without the food and water restrictions required for oral semaglutide, and Lilly has reported it can be manufactured at scale without the synthesis constraints associated with peptide drugs. Mechanistically, orforglipron preferentially enhances cyclic AMP signaling over β-arrestin recruitment, a profile associated with reduced receptor desensitization compared with full GLP-1 agonists.
- Compound class: small-molecule, non-peptide GLP-1 receptor agonist
- Mechanism: partial GLP-1 receptor agonism with biased signaling preference for cyclic AMP over β-arrestin recruitment, associated with reduced receptor desensitization compared with full GLP-1 agonists
- Synonyms: LY3502970, OWL-833
- CAS Number: 2212020-52-3
- Molecular Formula: C48H48F2N10O5
- Molecular Weight: 882.96 g/mol
- Developer: Eli Lilly and Company
- Administration: once daily, oral, no food or water restrictions
- Phase 3 program: ACHIEVE (type 2 diabetes, 5 trials) and ATTAIN (obesity, 3+ trials)
- Regulatory status: Lilly announced submission for weight management to global regulators by end of 2025; T2D submission anticipated 2026
Product Specifications
- Format: capsules
- Strength: 6 mg per capsule
- Count: 60 capsules per bottle
- Purity: ≥99% (HPLC verified)
- Container: sealed amber bottle
- Certificate of Analysis: lot-specific COA available
See the FDA Disclosure, Storage Instructions, and RUO tabs for handling, storage, and regulatory information.
References
- Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877-888. doi:10.1056/NEJMoa2302392
- Frias JP, Hsia S, Eyde S, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, concentration-response, phase 2 study. Lancet. 2023;402(10400):472-483. doi:10.1016/S0140-6736(23)01302-8
- Wharton S, Aronne LJ, Stefanski A, et al; ATTAIN-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. doi:10.1056/NEJMoa2511774
- Rosenstock J, Hsia S, Nevarez Ruiz L, et al; ACHIEVE-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025;393(11):1065-1076. doi:10.1056/NEJMoa2505669
Preparation and storage
Research-only handling information. Orforglipron is sold strictly for in vitro laboratory research. The handling and storage guidance below reflects standard practice in published peptide research literature. Orforglipron is not a drug, supplement, or food product, and is not for human consumption, veterinary use, or medical applications.
Format
- Form: Capsules
- Available strengths: 60ct
- Verified purity: >99% (HPLC, LC–MS)
- Documentation: Batch-specific Certificate of Analysis (COA) included
Handling for Research Use
Orforglipron capsules ship as a pre-encapsulated, dry oral-research format. No reconstitution is required. The capsules can be opened for analytical or assay work that requires the dry powder.
Storage & Handling
- Upon receipt: Store in a cool, dry place away from direct light.
- Short-term storage: Room temperature in a sealed container is acceptable for several months.
- Long-term storage: Refrigeration at 4 °C (39 °F) extends shelf stability. Capsules do not require freezing.
- Humidity: Keep the original desiccant-sealed container closed when not in use. Excess moisture can compromise capsule integrity.
- Light exposure: Minimize exposure to direct light during handling.
Important Notice
All Omnix Peptides products are sold for laboratory, research, or analytical purposes only. They are not for human consumption, veterinary use, or medical applications. Researchers and laboratory professionals must follow all applicable institutional, local, state, and federal regulations governing the handling of research compounds.
Citations
Citations and reference data. Omnix Peptides supplies research-grade compounds for use by qualified laboratory professionals. The references below cite published preclinical research conducted in animal models and in vitro systems. They are not intended to represent clinical evidence in humans, and Orforglipron has not been approved by the FDA, EMA, or any other regulatory authority for any indication.
Compound Reference Data
- Compound: Orforglipron
- CAS Number: 2212020-52-3
- Molecular Formula: C48H48F2N10O5
- Molecular Weight: 882.96 g/mol
- Sequence: —
- Synonyms: —
Selected Published Studies
The following peer-reviewed studies were conducted using animal models or in vitro cell-culture systems. They are listed here as a reference for researchers investigating Orforglipron. None of these studies should be interpreted as recommending Orforglipron for human use, treatment, or any clinical purpose.
- Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877-888. doi:10.1056/NEJMoa2302392
- Frias JP, Hsia S, Eyde S, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402(10400):472-483. doi:10.1016/S0140-6736(23)01302-8
- Wharton S, Aronne LJ, Stefanski A, et al; ATTAIN-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. doi:10.1056/NEJMoa2511774
- Rosenstock J, Hsia S, Nevarez Ruiz L, et al; ACHIEVE-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025;393(11):1065-1076. doi:10.1056/NEJMoa2505669
Evidence-Base Disclosure
The published evidence base for Orforglipron consists predominantly of preclinical research — animal models (often rats or mice) and in vitro cell-culture experiments. Where Phase I or Phase II human trials exist, they are noted in the compound page summary. Researchers should interpret the cited literature within the experimental context of each individual study.
Frequently asked questions
Frequently asked questions about the Orforglipron Capsules. Questions on this page cover handling, storage, documentation, and ordering. Orforglipron is sold for laboratory, research, or analytical purposes only — not for human consumption, veterinary use, or medical applications.
Why does Omnix offer Orforglipron in a capsule format?
Capsule format is used in oral-research and analytical contexts where dry, pre-measured administration is preferred over a reconstituted solution. The capsules contain the same research-grade compound supplied in the vial format and are tested to the same purity specification.
Do the Orforglipron capsules require refrigeration?
Capsules are stable at room temperature for several months when kept in a cool, dry place away from direct light. Refrigeration at 4 °C (39 °F) extends shelf stability and is recommended for long-term storage. Capsules do not require freezing.
Can the capsules be opened to access the dry powder?
Yes. The capsule shell can be opened for analytical or assay work that requires direct handling of the dry powder. Once opened, the powder should be used immediately or transferred to a sealed, light-protected container.
Is Orforglipron approved by the FDA?
No. Orforglipron is not approved by the FDA, EMA, or any other regulatory authority for any indication. Orforglipron is sold by Omnix Peptides strictly for laboratory, research, or analytical purposes. It is not for human consumption, veterinary use, or medical applications.
What is included with each Orforglipron Capsules?
Each order includes the sealed product container and a batch-specific Certificate of Analysis (COA) verifying identity and purity by HPLC and LC–MS. The full COA library for Omnix Peptides is available at /coa-lab-reports/.
What is a Certificate of Analysis (COA), and how do I read it?
A COA is a batch-specific lab report that documents the identity, purity, and quality control results for the production lot you receive. The COA lists the compound name, CAS number, lot number, analytical methods used (HPLC, LC–MS), and the measured purity percentage. Every Omnix order includes the COA for the lot shipped.
What is the CAS number for Orforglipron?
The CAS number for Orforglipron is 2212020-52-3. Researchers can use this identifier to locate published literature in PubMed and other scientific databases.
How does Omnix Peptides ship orders?
Orders ship from a US-based facility with tracked domestic shipping. Free shipping is offered on orders over $99. Lyophilized vials and capsules ship at ambient temperature; sprays ship insulated when seasonal conditions require it. Tracking information is provided by email after the order ships.
What if my product arrives damaged or the seal is broken?
Contact Omnix Peptides within 48 hours of delivery. Product damaged in transit or arriving with a compromised seal will be replaced at no cost. See the Shipping & Return Policy at /shipping-return-policy/ for full terms.
Where can I find published research on Orforglipron?
Peer-reviewed studies relevant to Orforglipron are listed in the Citations tab on this product page. The same studies can be located independently on PubMed using the CAS number (2212020-52-3) or the compound name.
Customer reviews
Certificate of Analysis
Third-party HPLC purity analysis performed by an independent laboratory for this batch.
Reviews
There are no reviews yet.